Menu
Back to Journals » Transplant Research and Risk Management » Volume 2
Low antigenicity of hematopoietic progenitor cells derived from human ES cells
Authors Eun-Mi Kim, Zavazava N
Published 3 February 2010 Volume 2010:2 Pages 15—22
DOI https://doi.org/10.2147/TRRM.S8272
Review by Single anonymous peer review
Peer reviewer comments 2
Eun-Mi Kim1, Nicholas Zavazava1,2
1Department of Internal Medicine, University of Iowa and Veterans Affairs Medical Center, Iowa City, Iowa, USA; 2Immunology Graduate Program, University of Iowa, Iowa City, Iowa, USA
Abstract: Human embryonic stem (hES) cells are essential for improved understanding of diseases and our ability to probe new therapies for use in humans. Currently, bone marrow cells and cord blood cells are used for transplantation into patients with hematopoietic malignancies, immunodeficiencies and in some cases for the treatment of autoimmune diseases. However, due to the high immunogenicity of these hematopoietic cells, toxic regimens of drugs are required for preconditioning and prevention of rejection. Here, we investigated the efficiency of deriving hematopoietic progenitor cells (HPCs) from the hES cell line H13, after co-culturing with the murine stromal cell line OP9. We show that HPCs derived from the H13 ES cells poorly express major histocompatibility complex (MHC) class I and no detectable class II antigens (HLA-DR). These characteristics make hES cell-derived hematopoietic cells (HPCs) ideal candidates for transplantation across MHC barriers under minimal immunosuppression.
Keywords: human embryonic stem cells, H13, hematopoiesis, OP9 stromal cells, immunogenicity
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.